0001171843-18-003112.txt : 20180426 0001171843-18-003112.hdr.sgml : 20180426 20180426171936 ACCESSION NUMBER: 0001171843-18-003112 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180426 DATE AS OF CHANGE: 20180426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PSYCHEMEDICS CORP CENTRAL INDEX KEY: 0000806517 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 581701987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-13738 FILM NUMBER: 18779775 BUSINESS ADDRESS: STREET 1: 125 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-206-8220 MAIL ADDRESS: STREET 1: 125 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 10-Q 1 f10q_042618p.htm FORM 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 10-Q

 

☒   Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

 

For the quarterly period ended March 31, 2018

or

 

☐  

Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

for the transition period from _________ to __________

 

Commission file number: 1-13738

 

PSYCHEMEDICS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   58-1701987
(State or Other Jurisdiction of
Incorporation or Organization)		   (I.R.S. Employer
Identification No.)

 

289 Great Road
Acton, MA		  

 

01720

(Address of Principal Executive Offices)   (Zip Code)

 

Registrant's telephone number including area code: (978) 206-8220

 

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐
  Accelerated filer ☒
  Non–accelerated filer ☐  [Do not check if a smaller reporting company]
  Smaller reporting company ☐
  Emerging growth company ☐

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☐ No ☒

 

The number of shares of Common Stock of the Registrant, par value $0.005 per share, outstanding at April 20, 2018 was 5,492,053.

 

1

 

PSYCHEMEDICS CORPORATION

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2018

 

INDEX

 

  Page
PART I - FINANCIAL INFORMATION  
   
Item 1 - Financial Statements  
  Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017 3
  Condensed Consolidated Statements of Income and Comprehensive Income for the Three months ended March 31, 2018 and 2017 4
  Condensed Consolidated Statements of Cash Flows for the Three months ended March 31, 2018 and 2017 5
  Notes to Condensed Consolidated Financial Statements 6
     
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations
     
  Overview 14
  Results of Operations 14
  Liquidity and Capital Resources 15
     
Item 3 - Quantitative and Qualitative Disclosures About Market Risk 16
   
Item 4 - Controls and Procedures 16
   
PART II - OTHER INFORMATION  
   
Item 1A - Risk Factors 17
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 17
Item 6 - Exhibits 17
   
Signatures 17
   
Exhibit Index 18

 

2

 

PSYCHEMEDICS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value)

(UNAUDITED)

 

   March 31,
2018		  December 31,
2017
       
ASSETS      
Current Assets:      
Cash and cash equivalents  $8,284   $8,165 
Accounts receivable, net of allowance for doubtful accounts of $69 in 2018 and $64 in 2017   6,062    4,488 
Prepaid expenses and other current assets   1,197    1,212 
Total Current Assets   15,543    13,865 
           
Fixed Assets, net of accumulated amortization and depreciation of $12,414 in 2018 and $11,670 in 2017    11,289    11,811 
Other assets   897    832 
           
Total Assets  $27,729   $26,508 
           
LIABILITIES AND SHAREHOLDERS' EQUITY          
           
Current Liabilities:          
Accounts payable  $327   $398 
Accrued expenses   3,888    2,870 
Current portion of long-term debt   957    957 
           
Total Current Liabilities   5,172    4,225 
           
Long-term debt   2,181    2,420 
Deferred tax liabilities, long-term   1,205    1,243 
Total Liabilities   8,558    7,888 
           
Commitments and Contingencies (Note 7)          
           
Shareholders' Equity:          
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding   --    -- 
Common stock, $0.005 par value; 50,000 shares authorized 6,160 shares issued in 2018 and 2017   31    31 
Accumulated other comprehensive loss   (250)   (238)
Additional paid-in capital   31,157    31,022 
Accumulated deficit   (1,685)   (2,113)
Less - Treasury stock, at cost, 668 shares   (10,082)   (10,082)
           
Total Shareholders' Equity   19,171    18,620 
           
Total Liabilities and Shareholders' Equity  $27,729   $26,508 

 

See accompanying notes to condensed consolidated financial statements

 

3

 

PSYCHEMEDICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(in thousands, except per share amounts)

(UNAUDITED)

 

   Three Months Ended
March 31,
   2018  2017
       
       
Revenues  $10,935   $10,209 
Cost of revenues   5,580    4,893 
           
Gross profit   5,355    5,316 
           
           
Operating Expenses:          
General & administrative   1,851    1,475 
Marketing & selling   1,239    1,243 
Research & development   359    330 
           
Total Operating Expenses   3,449    3,048 
           
Operating income   1,906    2,268 
Other income (expense)   32    (22)
           
Net income before provision for income taxes   1,938    2,246 
           
Provision for income taxes   687    746 
           
Net income  $1,251   $1,500 
           
Other Comprehensive Income (Loss):          
Foreign currency translation    (12)   -- 
Total Comprehensive Income  $1,239   $1,500 
           
Basic net income per share  $0.23   $0.27 
           
Diluted net income per share  $0.23   $0.27 
           
Dividends declared per share  $0.18   $0.15 

 

 

See accompanying notes to condensed consolidated financial statements

 

4

 

PSYCHEMEDICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(UNAUDITED)

 

   Three Months Ended
March 31,
   2018  2017
       
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income  $1,251   $1,500 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   753    687 
Deferred income taxes   (38)   (55)
Stock-based compensation   135    163 
Changes in assets and liabilities:          
Accounts receivable   (1,575)   2,050 
Prepaid expenses, other current assets, and income tax receivable   15    (92)
Accounts payable   (116)   (752)
Accrued expenses and accrued income taxes   981    901 
Net cash provided by operating activities   1,406    4,402 
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of equipment and leasehold improvements   (144)   (153)
Cost of internally developed software   --    (210)
Other assets   (74)   (3)
Net cash used in investing activities   (218)   (366)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payments of equipment financing   (239)   (286)
Cash dividends paid   (824)   (819)
Net cash used in financing activities   (1,063)   (1,105)
           
Effect of exchange rate changes on cash and cash equivalents   (6)   -- 
Net increase / (decrease) in cash and cash equivalents   119    2,931 
Cash and cash equivalents, beginning of period   8,165    3,938 
Cash and cash equivalents, end of period  $8,284   $6,869 
           
Supplemental Disclosures of Cash Flow Information:          
Cash paid for income taxes  $370   $29 
Cash paid for interest  $28   $22 
Purchases of equipment through accounts payable and accrued liabilities  $25   $11 

 

See accompanying notes to condensed consolidated financial statements

 

5

 


PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1.Basis of Presentation

 

The interim condensed consolidated financial statements of Psychemedics Corporation (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10-Q and do not include all the information and note disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2017, included in the Company's 2017 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission.

 

The condensed consolidated balance sheet as of March 31, 2018, the condensed consolidated statements of income and comprehensive income for the three-month periods ended March 31, 2018 and 2017, and the condensed consolidated statements of cash flows for the three-month periods ended March 31, 2018 and 2017 are unaudited but, in the opinion of management, include all adjustments necessary for a fair presentation of results for these interim periods. The condensed consolidated balance sheet as of December 31, 2017 has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm, but does not include all of the information and footnotes required for complete annual financial statements.

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended March 31, 2018 may not be indicative of the results that may be expected for the year ending December 31, 2018, or any other period.

 

Unless the context requires otherwise, the terms “we”, “us”, “our”, or “the Company” refer to Psychemedics Corporation and its consolidated subsidiaries.

 

2. Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents. Cash equivalents consisted exclusively of cash in the bank and bank certificates of deposits.

 

6

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

3.Stock-Based Compensation

 

The Company’s 2006 Incentive Plan (“the Plan”) provides for cash based awards or the grant or issuance of stock-based awards. As of March 31, 2018, 199 thousand shares remained available for future grant under the Plan.

 

A summary of the Company’s stock option activity for the three months ended March 31, 2018 is as follows (in 000’s except per share amounts):

 

   
 
 		  
 
 		  
Number of
Shares		  
 
 		 Weighted Average
Exercise Price
Per Share		  
 
 		 Weighted Average
Remaining
Contractual Life		  
 
 		 Aggregate
Intrinsic
Value(1)
  Outstanding, December 31, 2017   279   $15.40    8.7 years   $1,436 
  Granted   -                
  Exercised   -                
  Forfeited   -                
  Outstanding, March 31, 2018   279   $15.40    8.4 years   $1,659 
                       
  Exercisable, March 31, 2018   56   $12.61    7.9 years   $491 

 

(1)The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company’s stock on March 31, 2018 ($21.36) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option.

 

A summary of the Company’s stock unit award activity for the three months ended March 31, 2018 is as follows (in 000’s except per share amounts):

 

     Number of Shares  Weighted Average Price per Share (2)  Weighted Average Fair Value (2)
            
  Outstanding & Unvested, December 31, 2017   32   $16.08   $516 
  Granted   -           
  Converted to common stock   -           
  Cancelled   -           
  Forfeited   -           
  Outstanding & Unvested, March 31, 2018   32   $16.08   $516 

 

(2)Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each grant of stock unit awards. The weighted average fair value is the weighted average share price times the number of shares.

 

As of March 31, 2018, a total of 510 thousand shares of common stock were reserved for issuance under the Plan. As of March 31, 2018, the unamortized fair value of awards relating to outstanding SUAs and options was $0.8 million, which is expected to be amortized over a weighted average period of 2.7 years.

 

7

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

4.Basic and Diluted Net Income Per Share

 

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The number of dilutive common equivalent shares outstanding during the period was determined in accordance with the treasury-stock method. Common equivalent shares consisted of common stock issuable upon the exercise of outstanding options and common stock issuable upon the vesting of outstanding, unvested SUAs. Basic and diluted weighted average common shares outstanding for the three months ended March 31, 2018 and 2017 were as follows:

 

     Three Months Ended
     March 31,
2018		  March 31,
2017
  Weighted average common shares outstanding, basic   5,492    5,460 
  Dilutive common equivalent shares   64    73 
  Weighted average common shares outstanding, diluted   5,556    5,533 

 

5. Business Segment Reporting

 

The Company manages its operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. All Brazil sales are through one independent distributor, which is the only customer greater than 10% of sales. The Company’s revenues by geographic region are as follows:

 

     Three Months Ended
     March 31,
2018		  March 31,
2017
  Consolidated Revenue:      
  United States  $7,323   $6,468 
  Brazil   3,526    3,696 
  Other   86    45 
  Total Revenue  $10,935   $10,209 

 

6. Fair Value Measurements

 

The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, which are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company’s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company.

 

8

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

7. Subsequent Events

 

On April 24, 2018, the Company declared a quarterly dividend of $0.18 per share for a total of $989 thousand, which will be paid on May 18, 2018 to shareholders of record on May 8, 2018.

 

8.Commitments and Contingencies

 

The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. While the ultimate outcome of individual legal claims is inherently unpredictable, we believe that the final resolution of any pending actions will not have a material adverse effect on our results of operations, financial position, liquidity or capital resources.

 

9.Debt and Other Financing Arrangements

 

On March 20, 2014, the Company entered into an equipment financing arrangement (“Loan Agreement”) with Banc of America Leasing & Capital, LLC, which it amended on August 8, 2014, September 15, 2015 and October 30, 2017. The terms of this arrangement are detailed in the 10-K.

 

The weighted average interest rate for all notes related to the Loan Agreement for the quarter ended March 31, 2018 was 3.4%, and represented $28 thousand of interest expense as compared to a rate of 2.8% and interest expense of $22 thousand for the comparable period in 2017. As of March 31, 2018, the interest rate was 3.5% and there was $3.1 million of outstanding debt related to the loan. The Company was in compliance with all loan covenants as of March 31, 2018.

 

The annual principal repayment requirements for debt obligations as of March 31, 2018 were as follows (in 000’s):

 

  2018  $718 
  2019   891 
  2020   702 
  2021   446 
  2022   381 
  Total long-term debt   3,138 
  Less current portion of long-term debt   (957)
  Total long-term debt, net of current portion  $2,181 

 

10.Significant Customers

 

The Company had one customer that represented 32% of revenue for the three months ended March 31, 2018 and 36% for the total revenue for the three months ended March 31, 2017. The Company had two customers that exceeded 10% of the total accounts receivable balance as of March 31, 2018 and one customer that exceeded 10% of the total accounts receivable balance as of December 31, 2017.

 

9

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

11. Recently Adopted Accounting Pronouncements

 

In May 2014, the Financial Accounting Standard’s Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. The guidance in this update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (for example, insurance contracts or lease contracts). The guidance in this update supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition”, and most industry-specific guidance throughout the Industry Topics of the Codification.

 

Effective January 1, 2018, the Company adopted the requirements of Topic 606, “Revenue from Contracts with Customers,” using the modified retrospective method, which requires the recognition of the cumulative effect of initially applying the standard (if any) as an adjustment to opening retained earnings for the fiscal year beginning January 1, 2018.  The adoption of Topic 606 did not result in the recognition of a cumulative adjustment to opening retained earnings under the modified retrospective approach, nor did it have a material effect on the Company’s financial position or results of operations.  The adoption of this topic requires additional disclosures within the notes to the financial statements, as disclosed in Note 13 – “Revenue”.

 

12. Accounting Pronouncements Issued But Not Yet Effective

 

In February 2016, the FASB issued ASU 2016-02, “Leases”, which introduces the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. The new standard establishes a right-of-use ("ROU") model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. The new standard will become effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.

 

In February 2018, the FASB issued ASU 2018-02, “Income Statement – Reporting Comprehensive Income” (Topic 220) Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which will allow a reclassification from accumulated other comprehensive income to retained earnings for the tax effects resulting from the Tax Cuts and Jobs Act (Tax Reform Act) that are stranded in accumulated other comprehensive income. This standard also requires certain disclosures about stranded tax effects. ASU 2018-2, however, does not change the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations. ASU 2018-02 will be effective for the Company’s fiscal year 2020, with the option to early adopt at any time prior to the effective date. It must be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Reform Act is recognized. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.

 

10

 

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

12. Accounting Pronouncements Issued But Not Yet Effective (continued)

 

In March 2018, the FASB issued ASU 2018-05, “Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118”, which updates the income tax accounting in U.S. GAAP to reflect the Securities and Exchange Commission (“SEC”) interpretive guidance released on December 22, 2017, when the Tax Act was signed into law. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.

 

13. Revenue

 

Adoption of ASC Topic 606, “Revenue from Contracts with Customers”

 

On January 1, 2018, the Company adopted Topic 606 using the modified retrospective method.  The adoption of Topic 606 did not have a material effect on the Company’s financial position or results of operations.

 

Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (none of which is variable) we expect to be entitled to in exchange for those services. We typically invoice customers monthly for services provided and payments are generally due within 30 to 60 days of the invoice date.

 

The table below disaggregates our external revenue by major source.  For additional revenue detail relating to geographic breakdown of sales, see Note 5 – “Business Segment Reporting”.

 

     Three Months Ended
   
 		  
 		 March 31,
2018		  
 		 March 31,
2017
     (in 000's)
  Testing  $9,997   $9,385 
  Shipping/Collection (hair)   824    684 
  Other   114    140 
  Total Revenue  $10,935   $10,209 

 

Testing Revenue

 

Testing revenue is our primary service. This primarily represents drug and alcohol tests for drugs of abuse using hair, performed in our forensic laboratory in California. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer.  Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue.

 

11

 

PSYCHEMEDICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

13. Revenue (continued)

 

Revenue is measured as the amount of consideration we expect to receive in exchange for providing services.  Sales and other taxes we pay concurrent with revenue-producing activities are excluded from revenue. Incidental items, such as storage of samples and data, that are immaterial in the context of the contract are recognized as expense.   

 

Shipping and Hair Collection Revenue

 

Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (“sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third parties who have contracted with the Company. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer.  

 

Revenue is measured as the amount of consideration we expect to receive in exchange for providing services.  As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues.

 

Other Revenue

 

Other revenue represents several items including; urine testing performed by other labs, medical review officer charges, legal/testifying services, a retail test which is sent to the laboratory for testing, and other miscellaneous charges. The total of all of these items is approximately 1% of sales. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time.  

 

Practical Expedients and Exemptions

 

We generally expense sales commissions when incurred because the amortization period is one year or less. These costs are recorded within selling, general and administrative expense.

 

 

 

 

12

 

Item 2.

 

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

FACTORS THAT MAY AFFECT FUTURE RESULTS

 

From time to time, information provided by the Company or statements made by its employees may contain "forward-looking" information which involves risks and uncertainties. In particular, statements contained in this report which are not historical facts (including, but not limited to, the Company's expectations regarding earnings, earnings per share, revenues, operating cash flows, profitability, margins, pricing, dividends, future business, growth opportunities, new accounts, customer base, test volume, sales and marketing strategy, business strategy, general and administrative expenses, marketing and selling expenses, research and development expenses, anticipated operating results, foreign drug testing laws and regulations and the enforcement of such laws and regulations, including effective dates of such laws and regulations, required investments in plant, property and equipment, strategies with respect to governmental agencies and regulations, cost savings, capital expenditures, liquidity of investments and anticipated cash requirements) may be "forward-looking" statements. The Company's actual results may differ from those stated in any "forward-looking" statements. Factors that may cause such differences include, but are not limited to, risks associated with employee hiring practices of the Company’s principal customers, development of markets for new products and services offered by the Company, costs associated with capacity expansion, government regulation (including, but not limited to, Food and Drug Administration regulations and foreign government regulation including Brazilian commercial drivers license drug test laws and regulations), risks associated with the delay in the implementation of new regulations, risks associated with foreign currency fluctuations, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its global operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, and general economic conditions. With respect to the continued payment of cash dividends, factors include, but are not limited to, available surplus, cash flow, capital expenditure reserves required, debt service obligations, and other factors that the Board of Directors of the Company may take into account.

 

Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements represent the Company’s estimates and assumptions only as of the filing date of this Report. The Company expressly disclaim any duty to provide updates to forward-looking statements, and the estimates and assumptions associated with them, after the filing date of this Report, in order to reflect changes in circumstances or expectations, or the occurrence of unanticipated events, except to the extent required by applicable securities laws. All of the forward-looking statements are qualified in their entirety by reference to the factors discussed above and under “Risk Factors” set forth in Part I Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, as well as the risks and uncertainties discussed elsewhere in this Report. The Company qualifies all of its forward-looking statements by these cautionary statements. The Company cautions you that these risks are not exhaustive. The Company operates in a continually changing business environment and new risks emerge from time to time.

 

13

 

OVERVIEW

 

Revenue for the first quarter of 2018 was $10.9 million compared to $10.2 million in 2017, an increase of 7%. The Company reported net income of $1.3 million, or $0.23 per diluted share for the three months ended March 31, 2018 versus $1.5 million, or $0.27 per diluted share for the same period in 2017, a decrease of 17%. Our first quarter revenue represented the Company’s record results for any first quarter in the Company’s history. Earnings were impacted by several items described below. The Company distributed $0.8 million or $0.15 per share of cash dividends to its shareholders in the three months ended March 31, 2018. The Company has paid 86 consecutive quarterly cash dividends.

 

RESULTS OF OPERATIONS

 

Revenue growth of 7% noted above was primarily due to a 15% increase in volume, offset by an 8% decrease of average revenue per sample. The domestic business increased 13%. The international business decreased 3%.

 

Gross profit was $5.4 million for the three months ended March 31, 2018, compared to $5.3 million for the same period in 2017, an increase of $0.1 million, or 1%. Direct costs increased by $687 thousand or 14% for the three months ended March 31, 2018 compared to the same period in 2017. The gross profit margin was 49% for the three months ended March 31, 2018 and 52% for the comparable period of 2017. The margin was adversely impacted by Brazilian sales taxes and decrease in average revenue per sample noted above.

 

General and administrative (“G&A”) expenses increased $0.4 million to $1.9 million for the three months ended March 31, 2018 compared to $1.5 million for the same period in 2017. As a percentage of revenue, G&A expenses were 17% for the three months ended March 31, 2018 and 14% for the same period in 2017. There was an increase in professional fees related to the Company becoming an SEC accelerated filer as well as additional administrative costs related to our Brazil subsidiary, which was created in April 2017.

 

Marketing and selling expenses were $1.2 million for the three months ended March 31, 2018 and 2017. Total marketing and selling expenses represented 11% of revenue for the three months ended March 31, 2018 and 12% for the comparable period in 2017.

 

Research and development (“R&D”) expenses for the three months ended March 31, 2018 were $359 thousand compared to $330 thousand for the comparable period of 2017. R&D expenses represented 3% of revenue for the three months ended March 31, 2018 and 2017.

 

Provision for income taxes Our provision for income taxes consists primarily of federal and state income taxes in the United Sates and income taxes in Brazil. We estimate income taxes in each of the jurisdictions in which we operate. During the three months ended March 31, 2018 and 2017, the Company recorded tax provisions of $687 thousand and $746 thousand, respectively. These provisions represented effective tax rates of 35% for the three months ended March 31, 2018 and 33% for the comparable period of 2017. While the Company’s tax rate had a small increase from 33% to 35%, this reflects the inclusion of Brazilian income taxes (not present in 2017 first quarter as our Brazilian subsidiary started in the second quarter of 2017), partially offset by a reduction in the U.S. federal income tax rate. The Company currently expects the year-end tax rate to be to be approximately 35%.

 

14

 

LIQUIDITY AND CAPITAL RESOURCES

 

At March 31, 2018, the Company had approximately $8.3 million of cash. The Company's operating activities generated net cash of $1.4 million for the three months ended March 31, 2018. Investing activities used $218 thousand of cash while financing activities used $1.1 million of cash during the first three months of 2018.

 

Cash provided by operating activities of $1.4 million reflected net income of $1.3 million adjusted for depreciation and amortization of $753 thousand, stock-based compensation of $135 thousand and a decrease of deferred income taxes of $38 thousand. This was affected by the following changes in assets and liabilities: an increase in accounts receivable of $1.6 million, a decrease in prepaid expenses, other current assets and income tax receivable of $15 thousand, a decrease in accounts payable of $116 thousand and an increase in accrued expenses and income taxes of $1.0 million.

 

Cash used in investing activities included purchases of equipment and leasehold improvements of $144 thousand and other assets of $74 thousand. We anticipate spending $0.7 million to $1.2 million in additional capital purchases for the remainder of 2018.

 

Cash used by financing activities of $1.1 million included cash dividends to shareholders of $0.8 million and $0.2 million from payments on long term debt. On April 24, 2018, the Company declared a quarterly dividend of $0.18 per share for an estimated total of $989 thousand, which will be paid on May 18, 2018 to shareholders of record on May 8, 2018.

 

Contractual obligations and other commercial commitments as of March 31, 2018 were as follows (in 000’s):

 

     Less Than One Year  1-3
Years		  4-5
Years		  After 5 Years  Total
  Debt principal  $957   $1,488   $693   $-   $3,138 
  Operating leases   991    1,051    206    -    2,248 
  Total  $1,948   $2,539   $899   $-   $5,386 

 

At March 31, 2018, the Company's principal sources of liquidity included an aggregate of approximately $8.3 million of cash and cash equivalents and equipment financing line of credit availability of $1.9 million.  The Company had $10.4 million and $9.6 million of working capital as of March 31, 2018 and December 31, 2017, respectively. Management currently believes that such funds, together with cash generated from operations and future equipment financing, should be adequate to fund anticipated working capital and capital equipment requirements for the next 12 months.   Depending upon the Company's results of operations and capital needs, the Company may use various financing sources to raise additional funds. 

 

15

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

There have been no material changes in our Market Risks previously disclosed in Item 7A of our annual report on form 10-K for the year ended December 31, 2017.

 

Item 4. Controls and Procedures

 

As required by Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation as of December 31, 2017, under the supervision and with the participation of our management, including our Chief Executive Officer and Vice President of Finance, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act. As of December 31, 2017, management determined that it had failed to perform a timely and effective risk assessment over the financial reporting process and failed to maintain adequate documentation of how control activities address the financial statement risks, including the identification of key reports and design of controls in validating the completeness and accuracy of reports utilized in the revenue controls cycle. Accordingly, management determined that this control deficiency constituted a material weakness in internal control over financial reporting as of December 31, 2017, which was not fully remediated as of March 31, 2018. Based on the foregoing, management concluded that the Company's disclosure controls and procedures were not effective as of March 31, 2018.

 

However, management does not believe that this material weakness resulted in any material misstatement in the financial statements included in this Quarterly Report on Form 10-Q, or any previously issued financial statements.

 

Management will remediate this material weakness by evaluating our control environment and our risk assessment process, including the implementation and documentation of the control process and identification and testing of key revenue reports.

 

Other than the actions taken to continue remediation of the previously reported material weakness related to our control environment described above, there have been no significant changes in the Company's internal controls over financial reporting during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.

 

16

 

PART II OTHER INFORMATION

 

Item 1A. Risk Factors

 

There have been no material changes in our risk factors from those disclosed in our 2017 Annual Report on Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

There were no purchases of treasury stock in the first three months of 2018.

 

Item 6. Exhibits

 

See Exhibit Index included in this Report

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Psychemedics Corporation
       
Date: April 26, 2018 By: /s/ Raymond C. Kubacki  
    Raymond C. Kubacki  
    Chairman and Chief Executive Officer
    (principal executive officer)

 

Date: April 26, 2018 By: /s/ Neil L. Lerner  
    Neil L. Lerner  
    Vice President - Finance
    (principal accounting officer)

 

 

 

 

 

17

 

PSYCHEMEDICS CORPORATION

FORM 10-Q

March 31, 2018

EXHIBIT INDEX

 

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2 Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema
101.CAL XBRL Taxonomy Extension Calculation Linkbase
101.LAB XBRL Taxonomy Extension Label Linkbase
101.PRE XBRL Taxonomy Extension Presentation Linkbase
101.DEF XBRL Taxonomy Extension Definition Linkbase

 

 

 

 

18

 

 EX-31.1 2 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Raymond C. Kubacki, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Psychemedics Corporation (“the registrant”);

 

2.Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined by Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 26, 2018 By: /s/ Raymond C. Kubacki  
    Raymond C. Kubacki  
    Chairman and Chief Executive Officer
    (principal executive officer)

 

 

 

20

 

 EX-31.2 3 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Neil Lerner, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Psychemedics Corporation (“the registrant”);

 

2.Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined by Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 26, 2018 By: /s/ Neil L. Lerner  
    Neil L. Lerner  
    Vice President - Finance
    (principal accounting officer)

 

 

 

21

 

 EX-32.1 4 exh_321.htm EXHIBIT 32.1

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Raymond C. Kubacki, Chairman and Chief Executive Officer of Psychemedics Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as the principal executive officer of the Company, that:

 

(1)The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on April 26, 2018 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 26, 2018 By: /s/ Raymond C. Kubacki  
    Raymond C. Kubacki  
    Chairman and Chief Executive Officer
    (principal executive officer)

 

 

 

22

 

 EX-32.2 5 exh_322.htm EXHIBIT 32.2

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Neil Lerner, Vice President - Finance of Psychemedics Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as the principal accounting officer of the Company, that:

 

(1)The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on April 26, 2018 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 26, 2018 By: /s/ Neil L. Lerner  
    Neil L. Lerner  
    Vice President - Finance
    (principal accounting officer)

 

 

 

23

 

 EX-101.INS 6 pmd-20180331.xml XBRL INSTANCE FILE false --12-31 Q1 2018 2018-03-31 10-Q 0000806517 5492053 Yes Accelerated Filer PSYCHEMEDICS CORP No No pmd 981000 901000 1 1 2 1 1 239000 286000 16.08 16.08 516000 516000 327000 398000 6062000 4488000 3888000 2870000 12414000 11670000 -250000 -238000 31157000 31022000 69000 64000 27729000 26508000 15543000 13865000 8284000 8165000 3938000 6869000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></td> <td><div style="display: inline; font-weight: bold;">Cash and Cash Equivalents</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The Company considers all highly liquid investments with original maturities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div> days or less to be cash equivalents. Cash equivalents consisted exclusively of cash in the bank and bank certificates of deposits.</div></div> 119000 2931000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div></div></td> <td><div style="display: inline; font-weight: bold;">Commitments and Contingencies</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. While the ultimate outcome of individual legal claims is inherently unpredictable, we believe that the final resolution of any pending actions will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material adverse effect on our results of operations, financial position, liquidity or capital resources.</div></div> 510000 0.18 0.18 0.15 0.005 0.005 50000000 50000000 6160000 6160000 31000 31000 1239000 1500000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div></div></td> <td><div style="display: inline; font-weight: bold;">Significant Customers</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> </div>customer that represented <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32%</div> of revenue for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36%</div> for the total revenue for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017. </div>The Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> customers that exceeded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of the total accounts receivable balance as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> customer that exceeded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of the total accounts receivable balance as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017.</div></div></div> 0.1 0.32 0.36 0.01 0.01 5580000 4893000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></div></td> <td><div style="display: inline; font-weight: bold;">Debt and Other Financing Arrangements</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 20, 2014, </div>the Company entered into an equipment financing arrangement (&#x201c;Loan Agreement&#x201d;) with Banc of America Leasing &amp; Capital, LLC, which it amended on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 8, 2014, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 15, 2015 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 30, 2017. </div>The terms of this arrangement are detailed in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The weighted average interest rate for all notes related to the Loan Agreement for the quarter ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.4%,</div> and represented <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$28</div> thousand of interest expense as compared to a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.8%</div> and interest expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22</div> thousand for the comparable period in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>the interest rate was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.5%</div> and there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.1</div> million of outstanding debt related to the loan. The Company was in compliance with all loan covenants as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018.</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The annual principal repayment requirements for debt obligations as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>were as follows (in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">000&#x2019;s</div>):</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="width: 4%; background-color: White">&nbsp;</td> <td style="width: 75%; font-size: 10pt; text-align: left">2018</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 2%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right">718</td> <td style="width: 2%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">891</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">702</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left">2021</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">446</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2022</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">381</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left">Total long-term debt</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,138</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less current portion of long-term debt</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(957</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total long-term debt, net of current portion</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,181</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div> 0.035 0.034 0.028 1205000 1243000 753000 687000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div></div></td> <td><div style="display: inline; font-weight: bold;">Accounting Pronouncements Issued But <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Not</div> Yet Effective</div></td> </tr> </table> <div style=" font-size: 10pt; line-height: 12pt; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> &#x201c;Leases&#x201d;, which introduces the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. The new standard establishes a right-of-use ("ROU") model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months. The new standard will become effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018 </div>and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> &#x201c;Income Statement &#x2013; Reporting Comprehensive Income&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">220</div>) Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which will allow a reclassification from accumulated other comprehensive income to retained earnings for the tax effects resulting from the Tax Cuts and Jobs Act (Tax Reform Act) that are stranded in accumulated other comprehensive income. This standard also requires certain disclosures about stranded tax effects. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> however, does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> change the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> will be effective for the Company&#x2019;s fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020,</div> with the option to early adopt at any time prior to the effective date. It must be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Reform Act is recognized. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 10 --> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">05,</div>&nbsp;&#x201c;Income Taxes (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">740</div>): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118&#x201d;,</div> which updates the income tax accounting in U.S. GAAP to reflect the Securities and Exchange Commission (&#x201c;SEC&#x201d;) interpretive guidance released on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 22, 2017, </div>when the Tax Act was signed into law. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; min-; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2017</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; text-align: center">(in 000's)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 3%">&nbsp;</td> <td style="width: 61%; font-size: 10pt">Testing</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,997</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,385</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td style="font-size: 10pt; text-align: left">Shipping/Collection (hair)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">824</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">684</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total Revenue</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,935</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,209</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div></div></td> <td><div style="display: inline; font-weight: bold;">Stock-Based Compensation</div></td> </tr> </table> <div style=" font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The Company&#x2019;s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2006</div> Incentive Plan (&#x201c;the Plan&#x201d;) provides for cash based awards or the grant or issuance of stock-based awards. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">199</div> thousand shares remained available for future grant under the Plan.</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">A summary of the Company&#x2019;s stock option activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>is as follows (in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">000&#x2019;s</div> except per share amounts):</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;<br /> Number of<br /> Shares</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Exercise Price<br /> Per Share</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Remaining<br /> Contractual Life</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Aggregate<br /> Intrinsic<br /> Value<div style="display: inline; font-size: 10pt; font-weight: normal; font-style: normal"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(1)</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 2%; background-color: White">&nbsp;</td> <td style="width: 46%; font-size: 10pt">Outstanding, December 31, 2017</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">279</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.40</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.7 years</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,436</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">Outstanding, March 31, 2018</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">279</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.40</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.4 years</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,659</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">Exercisable, March 31, 2018</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">56</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.61</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.9 years</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">491</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 20.55pt"></td> <td style="width: 19.95pt"><div style="display: inline; color: #231F20">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)</div></td> <td style="text-align: justify; padding-right: 5.35pt">The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company&#x2019;s stock on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 (</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$21.36</div>) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option.</td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">A summary of the Company&#x2019;s stock unit award activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>is as follows (in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">000&#x2019;s</div> except per share amounts):</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Weighted Average Price per Share <div style="display: inline; font-size: 10pt; font-weight: normal; font-style: normal"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(2)</div></div></td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Weighted Average Fair Value <div style="display: inline; font-size: 10pt; font-weight: normal; font-style: normal"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(2)</div></div></td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 2%; background-color: White">&nbsp;</td> <td style="width: 59%; font-size: 10pt">Outstanding &amp; Unvested, December 31, 2017</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.08</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">516</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-left: 10pt">Granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Converted to common stock</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-left: 10pt">Cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">Outstanding &amp; Unvested, March 31, 2018</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.08</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">516</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in"></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #231F20; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 29.55pt"></td> <td style="width: 19.95pt">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>)</td> <td style="text-align: justify; padding-right: 27pt">Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each grant of stock unit awards. The weighted average fair value is the weighted average share price times the number of shares.</td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; text-indent: -27pt; margin: 0pt 0 0pt 58.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div> thousand shares of common stock were reserved for issuance under the Plan. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>the unamortized fair value of awards relating to outstanding SUAs and options was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.8</div> million, which is expected to be amortized over a weighted average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.7</div> years.</div></div> 2018-05-18 989000000 2018-05-08 0.23 0.27 0.23 0.27 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div></div></td> <td><div style="display: inline; font-weight: bold;">Basic and Diluted Net Income Per Share</div></td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The number of dilutive common equivalent shares outstanding during the period was determined in accordance with the treasury-stock method. Common equivalent shares consisted of common stock issuable upon the exercise of outstanding options and common stock issuable upon the vesting of outstanding, unvested SUAs. Basic and diluted weighted average common shares outstanding for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> were as follows:</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2017</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 3%; background-color: White">&nbsp;</td> <td style="width: 61%; font-size: 10pt">Weighted average common shares outstanding, basic</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,492</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,460</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Dilutive common equivalent shares</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">73</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">Weighted average common shares outstanding, diluted</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,556</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,533</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div> -6000 800000 P2Y255D <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.</div></div></td> <td><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.25in; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, which are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company&#x2019;s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company.</div></div> 1851000 1475000 5355000 5316000 1938000 2246000 687000 746000 370000 29000 -116000 -752000 1575000 -2050000 38000 55000 -15000 92000 28000 22000 28000 22000 8558000 7888000 27729000 26508000 5172000 4225000 3138000 957000 957000 718000 381000 446000 702000 891000 2181000 2420000 -1063000 -1105000 -218000 -366000 1406000 4402000 1251000 1500000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div></div></td> <td><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Pronouncements</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> the Financial Accounting Standard&#x2019;s Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> &#x201c;Revenue from Contracts with Customers&#x201d;. The guidance in this update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (for example, insurance contracts or lease contracts). The guidance in this update supersedes the revenue recognition requirements in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605,</div> &#x201c;Revenue Recognition&#x201d;, and most industry-specific guidance throughout the Industry Topics of the Codification.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">Effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company adopted the requirements of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> &#x201c;Revenue from Contracts with Customers,&#x201d; using the modified retrospective method, which requires the recognition of the cumulative effect of initially applying the standard (if any) as an adjustment to opening retained earnings for the fiscal year beginning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div>&nbsp; The adoption of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div> did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> result in the recognition of a cumulative adjustment to opening retained earnings under the modified retrospective approach, nor did it have a material effect on the Company&#x2019;s financial position or results of operations.&nbsp; The adoption of this topic requires additional disclosures within the notes to the financial statements, as disclosed in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div> &#x2013; &#x201c;Revenue&#x201d;.</div></div> 25000 11000 1 3449000 3048000 1906000 2268000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></td> <td><div style="display: inline; font-weight: bold;">Basis of Presentation</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The interim condensed consolidated financial statements of Psychemedics Corporation (the &#x201c;Company&#x201d;) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include all the information and note disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>included in the Company's <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K, as filed with the Securities and Exchange Commission.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The condensed consolidated balance sheet as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>the condensed consolidated statements of income and comprehensive income for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and the condensed consolidated statements of cash flows for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> are unaudited but, in the opinion of management, include all adjustments necessary for a fair presentation of results for these interim periods. The condensed consolidated balance sheet as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>has been derived from the Company&#x2019;s annual financial statements that were audited by an independent registered public accounting firm, but does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include all of the information and footnotes required for complete annual financial statements.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be indicative of the results that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be expected for the year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>or any other period.</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">Unless the context requires otherwise, the terms &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, or &#x201c;the Company&#x201d; refer to Psychemedics Corporation and its consolidated subsidiaries.</div></div> 897000 832000 -12000 32000 -22000 74000 3000 824000 819000 144000 153000 210000 0.005 0.005 873000 873000 0 0 0 0 1197000 1212000 11289000 11811000 359000 330000 -1685000 -2113000 9997000 9385000 824000 684000 114000 140000 10935000 10209000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div></div></td> <td><div style="display: inline; font-weight: bold;">Revenue</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Adoption of ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> &#x201c;Revenue from Contracts with Customers&#x201d;</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company adopted Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div> using the modified retrospective method.&nbsp; The adoption of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div> did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material effect on the Company&#x2019;s financial position or results of operations.</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">none</div> of which is variable) we expect to be entitled to in exchange for those services. We typically invoice customers monthly for services provided and payments are generally due within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div> days of the invoice date.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in">The table below disaggregates our external revenue by major source.&nbsp; For additional revenue detail relating to geographic breakdown of sales, see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> &#x2013; &#x201c;Business Segment Reporting&#x201d;.</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in"></div> <div> <table style="border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2017</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; text-align: center">(in 000's)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 3%">&nbsp;</td> <td style="width: 61%; font-size: 10pt">Testing</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,997</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,385</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td style="font-size: 10pt; text-align: left">Shipping/Collection (hair)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">824</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">684</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total Revenue</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,935</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,209</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in"></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><div style="display: inline; font-weight: bold;">Testing Revenue</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Testing revenue is our primary service. This primarily represents drug and alcohol tests for drugs of abuse using hair, performed in our forensic laboratory in California. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (&#x201c;CCF&#x201d;) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. &nbsp;Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue.</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in"></div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in"></div> <!-- Field: Page; Sequence: 11 --> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Revenue is measured as the amount of consideration we expect to receive in exchange for providing services.&nbsp; Sales and other taxes we pay concurrent with revenue-producing activities are excluded from revenue. Incidental items, such as storage of samples and data, that are immaterial in the context of the contract are recognized as expense.&nbsp;&nbsp;&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><div style="display: inline; font-weight: bold;">Shipping and Hair Collection Revenue</div></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (&#x201c;sample&#x201d;) to the Company&#x2019;s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties who have contracted with the Company. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer. &nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Revenue is measured as the amount of consideration we expect to receive in exchange for providing services.&nbsp; As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Other Revenue</div></div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other revenue represents several items including; urine testing performed by other labs, medical review officer charges, legal/testifying services, a retail test which is sent to the laboratory for testing, and other miscellaneous charges. The total of all of these items is approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1%</div> of sales. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time. &nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Practical Expedients and Exemptions</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.25in">We generally expense sales commissions when incurred because the amortization period is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year or less. These costs are recorded within selling, general and administrative expense.</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2017</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">Consolidated Revenue:</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 3%; background-color: White">&nbsp;</td> <td style="width: 61%; font-size: 10pt; text-align: left; padding-left: 10pt">United States</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,323</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,468</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td style="font-size: 10pt; padding-left: 10pt">Brazil</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,526</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,696</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total Revenue</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,935</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,209</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> 7323000 6468000 3526000 3696000 86000 45000 10935000 10209000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; min-; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="width: 4%; background-color: White">&nbsp;</td> <td style="width: 75%; font-size: 10pt; text-align: left">2018</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 2%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right">718</td> <td style="width: 2%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left">2019</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">891</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left">2020</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">702</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left">2021</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">446</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2022</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">381</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left">Total long-term debt</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,138</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less current portion of long-term debt</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(957</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total long-term debt, net of current portion</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,181</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Weighted Average Price per Share <div style="display: inline; font-size: 10pt; font-weight: normal; font-style: normal"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(2)</div></div></td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Weighted Average Fair Value <div style="display: inline; font-size: 10pt; font-weight: normal; font-style: normal"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(2)</div></div></td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 2%; background-color: White">&nbsp;</td> <td style="width: 59%; font-size: 10pt">Outstanding &amp; Unvested, December 31, 2017</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.08</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">516</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-left: 10pt">Granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Converted to common stock</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-left: 10pt">Cancelled</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">Outstanding &amp; Unvested, March 31, 2018</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.08</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">516</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;<br /> Number of<br /> Shares</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Exercise Price<br /> Per Share</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Remaining<br /> Contractual Life</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;<br /> &nbsp;<br /> &nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Aggregate<br /> Intrinsic<br /> Value<div style="display: inline; font-size: 10pt; font-weight: normal; font-style: normal"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(1)</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 2%; background-color: White">&nbsp;</td> <td style="width: 46%; font-size: 10pt">Outstanding, December 31, 2017</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">279</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.40</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.7 years</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,436</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Granted</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Exercised</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">Outstanding, March 31, 2018</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">279</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.40</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.4 years</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,659</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">Exercisable, March 31, 2018</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">56</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.61</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.9 years</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">491</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2017</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 3%; background-color: White">&nbsp;</td> <td style="width: 61%; font-size: 10pt">Weighted average common shares outstanding, basic</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,492</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,460</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Dilutive common equivalent shares</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">73</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">Weighted average common shares outstanding, diluted</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,556</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,533</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0"></td> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.</div></div></td> <td><div style="display: inline; font-weight: bold;">Business Segment Reporting</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The Company manages its operations as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company&#x2019;s principal operating segment. All Brazil sales are through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> independent distributor, which is the only customer greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of sales. The Company&#x2019;s revenues by geographic region are as follows:</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2018</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<br /> 2017</td> </tr> <tr style="vertical-align: bottom"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt">Consolidated Revenue:</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 3%; background-color: White">&nbsp;</td> <td style="width: 61%; font-size: 10pt; text-align: left; padding-left: 10pt">United States</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,323</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 15%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,468</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td style="font-size: 10pt; padding-left: 10pt">Brazil</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,526</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,696</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="background-color: White">&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total Revenue</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,935</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,209</div></td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table> </div></div> 1239000 1243000 135000 163000 32000 32000 199000 56000 12.61 1436000 1659000 279000 279000 15.40 15.40 21.36 491000 P7Y328D P8Y255D P8Y146D 19171000 18620000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0.25in"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div></div></td> <td><div style="display: inline; font-weight: bold;">Subsequent Events</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.25in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 24, 2018, </div>the Company declared a quarterly dividend of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.18</div> per share for a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$989</div> thousand, which will be paid on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">May 18, 2018</div> </div>to shareholders of record on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">May 8, 2018</div>.</div></div></div> 668000 668000 10082000 10082000 64000 73000 5556000 5533000 5492000 5460000 The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company's stock on March 31, 2018 ($21.36) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option. Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each grant of stock unit awards. The weighted average fair value is the weighted average share price times the number of shares. xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000806517 2017-01-01 2017-03-31 0000806517 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-03-31 0000806517 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember pmd:OtherRevenueMember 2017-01-01 2017-03-31 0000806517 pmd:OtherRevenueMember 2017-01-01 2017-03-31 0000806517 pmd:ShippingCollectionHairMember 2017-01-01 2017-03-31 0000806517 pmd:TestingMember 2017-01-01 2017-03-31 0000806517 country:BR 2017-01-01 2017-03-31 0000806517 pmd:OtherForeignCountriesMember 2017-01-01 2017-03-31 0000806517 country:US 2017-01-01 2017-03-31 0000806517 2017-01-01 2017-12-31 0000806517 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0000806517 2018-01-01 2018-03-31 0000806517 pmd:StockUnitAwardMember 2018-01-01 2018-03-31 0000806517 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0000806517 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31 0000806517 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember country:BR 2018-01-01 2018-03-31 0000806517 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember pmd:OtherRevenueMember 2018-01-01 2018-03-31 0000806517 pmd:OtherRevenueMember 2018-01-01 2018-03-31 0000806517 pmd:ShippingCollectionHairMember 2018-01-01 2018-03-31 0000806517 pmd:TestingMember 2018-01-01 2018-03-31 0000806517 country:BR 2018-01-01 2018-03-31 0000806517 pmd:OtherForeignCountriesMember 2018-01-01 2018-03-31 0000806517 country:US 2018-01-01 2018-03-31 0000806517 us-gaap:SubsequentEventMember 2018-04-24 2018-04-24 0000806517 2016-12-31 0000806517 2017-03-31 0000806517 2017-12-31 0000806517 pmd:StockUnitAwardMember 2017-12-31 0000806517 2018-03-31 0000806517 pmd:StockUnitAwardMember 2018-03-31 0000806517 pmd:StockIncentivePlan2006Member 2018-03-31 0000806517 2018-04-20 0000806517 us-gaap:SubsequentEventMember 2018-04-24 EX-101.SCH 7 pmd-20180331.xsd XBRL SCHEMA FILE 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Cash and Cash Equivalents link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 3 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 4 - Basic and Diluted Net Income Per Share link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Business Segment Reporting link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 6 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 7 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 8 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 9 - Debt and Other Financing Agreements link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 10 - Significant Customers link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 11 - Recently Adopted Accounting Pronouncements link:calculationLink link:definitionLink link:presentationLink 016 - Document - Note 12 - Accounting Pronouncements Issued But Not Yet Effective link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 13 - Revenue link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 3 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 4 - Basic and Diluted Net Income Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 5 - Business Segment Reporting (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 9 - Debt and Other Financing Agreements (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 13 - Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 3 - Stock-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 3 - Share-based Compensation - Nonvested Award Activity (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 4 - Basic and Diluted Net Income Per Share - Basic and Diluted Shares Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 5 - Business Segment Reporting (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - Business Segment Reporting - Summary of Revenues by Geographic Region (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 7 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 9 - Debt and Other Financing Agreements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 10 - Significant Customers (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 13 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 13 - Revenue - Revenue by Major Source (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 pmd-20180331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 pmd-20180331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 pmd-20180331_lab.xml XBRL LABEL FILE Document And Entity Information Note To Financial Statement Details Textual Note 3 - Stock-based Compensation Note 4 - Basic and Diluted Net Income Per Share Note 5 - Business Segment Reporting Note 9 - Debt and Other Financing Agreements Note 13 - Revenue Note 3 - Stock-based Compensation - Stock Option Activity (Details) Note 3 - Share-based Compensation - Nonvested Award Activity (Details) Note 4 - Basic and Diluted Net Income Per Share - Basic and Diluted Shares Outstanding (Details) Note 5 - Business Segment Reporting - Summary of Revenues by Geographic Region (Details) Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) Note 13 - Revenue - Revenue by Major Source (Details) Notes To Financial Statements Other assets Stock-based compensation Notes To Financial Statements [Abstract] us-gaap_LiabilitiesCurrent Total Current Liabilities us-gaap_Revenues Revenues Operating Expenses: Share-based Compensation, Stock Options, Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited (in shares) Foreign currency translation us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Outstanding & Unvested (in shares) Outstanding & Unvested (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Granted (in shares) Depreciation and amortization Current portion of long-term debt Less current portion of long-term debt Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Exercisable, weighted average exercise price (in dollars per share) us-gaap_AssetsCurrent Total Current Assets Exercisable, Weighted average remaining contractual life (Year) Exercisable, aggregate intrinsic value Exercisable (in shares) Outstanding, Weighted average remaining contractual life (Year) Outstanding, aggregate intrinsic value Treasury stock, shares (in shares) Common stock, $0.005 par value; 50,000 shares authorized 6,160 shares issued in 2018 and 2017 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Adjustments to reconcile net income to net cash provided by operating activities: Common stock, shares authorized (in shares) Forfeited, weighted average exercise price (in dollars per share) Common stock, shares issued (in shares) Purchases of equipment through accounts payable and accrued liabilities Common stock, par value (in dollars per share) Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued expenses us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance Accounts payable Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding (in shares) Outstanding (in shares) Product and Service [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Forfeited (in shares) Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding Preferred stock, shares issued (in shares) Cash paid for interest us-gaap_PolicyTextBlockAbstract Accounting Policies Cash paid for income taxes Geographical [Axis] Geographical [Domain] Preferred stock, shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Preferred stock, par value (in dollars per share) us-gaap_PaymentsToDevelopSoftware Cost of internally developed software Revenues us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of equipment and leasehold improvements Current Liabilities: us-gaap_Assets Total Assets Supplemental Disclosures of Cash Flow Information: Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total CASH FLOWS FROM OPERATING ACTIVITIES: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Statement [Line Items] Allowance for doubtful accounts us-gaap_NumberOfOperatingSegments Number of Operating Segments Accounts receivable, net of allowance for doubtful accounts of $69 in 2018 and $64 in 2017 Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Additional paid-in capital Shareholders' Equity: Other income (expense) Segment Reporting Disclosure [Text Block] Equity Award [Domain] Current Assets: Fair Value Disclosures [Text Block] Award Type [Axis] Net income Net income us-gaap_Liabilities Total Liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Commitments and Contingencies (Note 7) us-gaap_OperatingIncomeLoss Operating income us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Accrued expenses and accrued income taxes The increase (decrease) during the reporting period in the aggregate amount of expenses and income taxes incurred but not yet paid. Effect of exchange rate changes on cash and cash equivalents us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net increase / (decrease) in cash and cash equivalents us-gaap_GrossProfit Gross profit pmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod Converted to common stock (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that were converted to common stock during the reporting period. Cost of revenues pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod Cancelled (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period. pmd_PaymentsOfEquipmentFinancing Payments of equipment financing The cash outflow in relating to equity financing during the year. Stock Incentive Plan 2006 [Member] Related to the stock incentive plan 2006. Outstanding & Unvested, weighted average fair value Weighted average fair value at which grantees can acquire the shares reserved for issuance under the equity instrument other than option. Granted, weighted average fair value Weighted average grant date fair value at which grantees can acquire shares of common stock by exercise of equity instrument other than option. pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAndNonvestedWeightedAverageExercisePrice Outstanding & Unvested, weighted average price per share (in dollars per share) Outstanding & Unvested, weighted average price per share (in dollars per share) Weighted average price at which grantees can acquire the shares reserved for issuance under the equity instrument other than option. pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice Granted, weighted average price per share (in dollars per share) Weighted average per share amount at which grantees can acquire shares of common stock by exercise of equity instrument other than option. Commitments and Contingencies Disclosure [Text Block] Accumulated amortization and depreciation Fixed Assets, net of accumulated amortization and depreciation of $12,414 in 2018 and $11,670 in 2017 Stock Unit Award [Member] Related to stock unit awards. pmd_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. us-gaap_PaymentsOfDividendsCommonStock Cash dividends paid CASH FLOWS FROM INVESTING ACTIVITIES: Earnings Per Share [Text Block] BRAZIL Provision for income taxes Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-term Debt, Total Total long-term debt Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Testing [Member] Represents testing services. Other Revenue [Member] Represents other revenue sources not otherwise disclosed. us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Net income before provision for income taxes us-gaap_OperatingExpenses Total Operating Expenses General & administrative Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Text Block] Amendment Flag Other Comprehensive Income (Loss): Accounting Policies [Abstract] us-gaap_ComprehensiveIncomeNetOfTax Total Comprehensive Income Concentration Risk Disclosure [Text Block] Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Preferred stock, shares outstanding (in shares) us-gaap_DebtWeightedAverageInterestRate Debt, Weighted Average Interest Rate Other Foreign Countries [Member] Information related to other foreign countries. Current Fiscal Year End Date Shipping/Collection (Hair) [Member] Information pertaining to shipping and hair collection services. us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses, other current assets, and income tax receivable Document Fiscal Period Focus Document Fiscal Year Focus us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Deferred income taxes Document Period End Date Document Type Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Dilutive common equivalent shares (in shares) us-gaap_SharePrice Share Price Schedule of Long-term Debt Instruments [Table Text Block] us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Weighted average common shares outstanding, diluted (in shares) us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Central Index Key Entity Registrant Name Product Concentration Risk [Member] Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Statement [Table] Scenario [Axis] Statement of Financial Position [Abstract] Diluted net income per share (in dollars per share) Scenario, Unspecified [Domain] Weighted average common shares outstanding, basic (in shares) Basic net income per share (in dollars per share) Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_TreasuryStockValue Less - Treasury stock, at cost, 668 shares Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding (in shares) Income Statement [Abstract] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2020 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour 2021 Sales Revenue, Net [Member] Revenue from External Customers by Geographic Areas [Table Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive 2022 Accounts Receivable [Member] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2018 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2019 Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Description of New Accounting Pronouncements Not yet Adopted [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Exercised (in shares) us-gaap_TableTextBlock Notes Tables New Accounting Pronouncements and Changes in Accounting Principles [Text Block] us-gaap_DividendPayableDateToBePaidDayMonthAndYear Dividends Payable, Date to be Paid us-gaap_PaymentsForProceedsFromOtherInvestingActivities Other assets Granted (in shares) CASH FLOWS FROM FINANCING ACTIVITIES: Marketing & selling us-gaap_DividendsPayableDateOfRecordDayMonthAndYear Dividends Payable, Date of Record us-gaap_DividendsPayableCurrentAndNoncurrent Dividends Payable us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Shareholders' Equity Deferred tax liabilities, long-term UNITED STATES Accumulated deficit Research & development Accumulated other comprehensive loss Debt Disclosure [Text Block] us-gaap_InterestExpense Interest Expense, Total Changes in assets and liabilities: us-gaap_StockholdersEquity Total Shareholders' Equity us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] Class of Stock [Axis] Long-term debt Total long-term debt, net of current portion Subsequent Event Type [Axis] Cash and Cash Equivalents Disclosure [Text Block] Subsequent Event Type [Domain] Subsequent Events [Text Block] Schedule of Weighted Average Number of Shares [Table Text Block] EX-101.PRE 11 pmd-20180331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document And Entity Information - shares
 3 Months Ended
Mar. 31, 2018
Apr. 20, 2018
Document Information [Line Items]    
Entity Registrant Name PSYCHEMEDICS CORP  
Entity Central Index Key 0000806517  
Trading Symbol pmd  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Entity Common Stock, Shares Outstanding (in shares)   5,492,053
Document Type 10-Q  
Document Period End Date Mar. 31, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current Assets:    
Cash and cash equivalents $ 8,284 $ 8,165
Accounts receivable, net of allowance for doubtful accounts of $69 in 2018 and $64 in 2017 6,062 4,488
Prepaid expenses and other current assets 1,197 1,212
Total Current Assets 15,543 13,865
Fixed Assets, net of accumulated amortization and depreciation of $12,414 in 2018 and $11,670 in 2017 11,289 11,811
Other assets 897 832
Total Assets 27,729 26,508
Current Liabilities:    
Accounts payable 327 398
Accrued expenses 3,888 2,870
Current portion of long-term debt 957 957
Total Current Liabilities 5,172 4,225
Long-term debt 2,181 2,420
Deferred tax liabilities, long-term 1,205 1,243
Total Liabilities 8,558 7,888
Commitments and Contingencies (Note 7)
Shareholders' Equity:    
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding
Common stock, $0.005 par value; 50,000 shares authorized 6,160 shares issued in 2018 and 2017 31 31
Accumulated other comprehensive loss (250) (238)
Additional paid-in capital 31,157 31,022
Accumulated deficit (1,685) (2,113)
Less - Treasury stock, at cost, 668 shares (10,082) (10,082)
Total Shareholders' Equity 19,171 18,620
Total Liabilities and Shareholders' Equity $ 27,729 $ 26,508
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
shares in Thousands, $ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Allowance for doubtful accounts $ 69 $ 64
Accumulated amortization and depreciation $ 12,414 $ 11,670
Preferred stock, par value (in dollars per share) $ 0.005 $ 0.005
Preferred stock, shares authorized (in shares) 873 873
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.005 $ 0.005
Common stock, shares authorized (in shares) 50,000 50,000
Common stock, shares issued (in shares) 6,160 6,160
Treasury stock, shares (in shares) 668 668
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenues $ 10,935 $ 10,209
Cost of revenues 5,580 4,893
Gross profit 5,355 5,316
Operating Expenses:    
General & administrative 1,851 1,475
Marketing & selling 1,239 1,243
Research & development 359 330
Total Operating Expenses 3,449 3,048
Operating income 1,906 2,268
Other income (expense) 32 (22)
Net income before provision for income taxes 1,938 2,246
Provision for income taxes 687 746
Net income 1,251 1,500
Other Comprehensive Income (Loss):    
Foreign currency translation (12)
Total Comprehensive Income $ 1,239 $ 1,500
Basic net income per share (in dollars per share) $ 0.23 $ 0.27
Diluted net income per share (in dollars per share) 0.23 0.27
Dividends declared per share (in dollars per share) $ 0.18 $ 0.15
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 1,251 $ 1,500
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 753 687
Deferred income taxes (38) (55)
Stock-based compensation 135 163
Changes in assets and liabilities:    
Accounts receivable (1,575) 2,050
Prepaid expenses, other current assets, and income tax receivable 15 (92)
Accounts payable (116) (752)
Accrued expenses and accrued income taxes 981 901
Net cash provided by operating activities 1,406 4,402
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment and leasehold improvements (144) (153)
Cost of internally developed software (210)
Other assets (74) (3)
Net cash used in investing activities (218) (366)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments of equipment financing (239) (286)
Cash dividends paid (824) (819)
Net cash used in financing activities (1,063) (1,105)
Effect of exchange rate changes on cash and cash equivalents (6)
Net increase / (decrease) in cash and cash equivalents 119 2,931
Cash and cash equivalents, beginning of period 8,165 3,938
Cash and cash equivalents, end of period 8,284 6,869
Supplemental Disclosures of Cash Flow Information:    
Cash paid for income taxes 370 29
Cash paid for interest 28 22
Purchases of equipment through accounts payable and accrued liabilities $ 25 $ 11
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 1 - Basis of Presentation
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
1.
Basis of Presentation
 
The interim condensed consolidated financial statements of Psychemedics Corporation (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form
10
-Q and do
not
include all the information and note disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended
December 31, 2017,
included in the Company's
2017
Annual Report on Form
10
-K, as filed with the Securities and Exchange Commission.
 
The condensed consolidated balance sheet as of
March 31, 2018,
the condensed consolidated statements of income and comprehensive income for the
three
-month periods ended
March 31, 2018
and
2017,
and the condensed consolidated statements of cash flows for the
three
-month periods ended
March 31, 2018
and
2017
are unaudited but, in the opinion of management, include all adjustments necessary for a fair presentation of results for these interim periods. The condensed consolidated balance sheet as of
December 31, 2017
has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm, but does
not
include all of the information and footnotes required for complete annual financial statements.
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the
three
months ended
March 31, 2018
may
not
be indicative of the results that
may
be expected for the year ending
December 31, 2018,
or any other period.
 
Unless the context requires otherwise, the terms “we”, “us”, “our”, or “the Company” refer to Psychemedics Corporation and its consolidated subsidiaries.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 2 - Cash and Cash Equivalents
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Cash and Cash Equivalents Disclosure [Text Block]
2.
Cash and Cash Equivalents
 
The Company considers all highly liquid investments with original maturities of
90
days or less to be cash equivalents. Cash equivalents consisted exclusively of cash in the bank and bank certificates of deposits.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Stock-based Compensation
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
3.
Stock-Based Compensation
 
The Company’s
2006
Incentive Plan (“the Plan”) provides for cash based awards or the grant or issuance of stock-based awards. As of
March 31, 2018,
199
thousand shares remained available for future grant under the Plan.
 
A summary of the Company’s stock option activity for the
three
months ended
March 31, 2018
is as follows (in
000’s
except per share amounts):
 
   
 
 		  
 
 		  
Number of
Shares		  
 
 		 Weighted Average
Exercise Price
Per Share		  
 
 		 Weighted Average
Remaining
Contractual Life		  
 
 		 Aggregate
Intrinsic
Value
(1)
  Outstanding, December 31, 2017    
279
     $
15.40
      
8.7 years
     $
1,436
  
  Granted    
-
      
 
      
 
      
 
  
  Exercised    
-
      
 
      
 
      
 
  
  Forfeited    
-
      
 
      
 
      
 
  
  Outstanding, March 31, 2018    
279
     $
15.40
      
8.4 years
     $
1,659
  
                                   
  Exercisable, March 31, 2018    
56
     $
12.61
      
7.9 years
     $
491
  
 
(
1
)
 The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company’s stock on
March 31, 2018 (
$21.36
) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option.
 
A summary of the Company’s stock unit award activity for the
three
months ended
March 31, 2018
is as follows (in
000’s
except per share amounts):
 
      Number of Shares   Weighted Average Price per Share
(2)
   Weighted Average Fair Value
(2)
               
  Outstanding & Unvested, December 31, 2017    
32
     $
16.08
     $
516
  
  Granted    
-
      
 
      
 
  
  Converted to common stock    
-
      
 
      
 
  
  Cancelled    
-
      
 
      
 
  
  Forfeited    
-
      
 
      
 
  
  Outstanding & Unvested, March 31, 2018    
32
     $
16.08
     $
516
  
 
(
2
)		 Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each grant of stock unit awards. The weighted average fair value is the weighted average share price times the number of shares.
 
As of
March 31, 2018,
a total of
510
thousand shares of common stock were reserved for issuance under the Plan. As of
March 31, 2018,
the unamortized fair value of awards relating to outstanding SUAs and options was
$0.8
million, which is expected to be amortized over a weighted average period of
2.7
years.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 4 - Basic and Diluted Net Income Per Share
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Earnings Per Share [Text Block]
4.
Basic and Diluted Net Income Per Share
 
Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The number of dilutive common equivalent shares outstanding during the period was determined in accordance with the treasury-stock method. Common equivalent shares consisted of common stock issuable upon the exercise of outstanding options and common stock issuable upon the vesting of outstanding, unvested SUAs. Basic and diluted weighted average common shares outstanding for the
three
months ended
March 31, 2018
and
2017
were as follows:
 
      Three Months Ended
      March 31,
2018		   March 31,
2017
  Weighted average common shares outstanding, basic    
5,492
      
5,460
  
  Dilutive common equivalent shares    
64
      
73
  
  Weighted average common shares outstanding, diluted    
5,556
      
5,533
  
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 5 - Business Segment Reporting
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
5.
Business Segment Reporting
 
The Company manages its operations as
one
segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. All Brazil sales are through
one
independent distributor, which is the only customer greater than
10%
of sales. The Company’s revenues by geographic region are as follows:
 
      Three Months Ended
      March 31,
2018		   March 31,
2017
  Consolidated Revenue:        
  United States   $
7,323
     $
6,468
  
  Brazil    
3,526
      
3,696
  
  Other    
86
      
45
  
  Total Revenue   $
10,935
     $
10,209
  
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 6 - Fair Value Measurements
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Fair Value Disclosures [Text Block]
6.
Fair Value Measurements
 
The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, which are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company’s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Subsequent Events
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Subsequent Events [Text Block]
7.
Subsequent Events
 
On
April 24, 2018,
the Company declared a quarterly dividend of
$0.18
per share for a total of
$989
thousand, which will be paid on
May 18, 2018
to shareholders of record on
May 8, 2018
.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 8 - Commitments and Contingencies
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
8.
Commitments and Contingencies
 
The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. While the ultimate outcome of individual legal claims is inherently unpredictable, we believe that the final resolution of any pending actions will
not
have a material adverse effect on our results of operations, financial position, liquidity or capital resources.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 9 - Debt and Other Financing Agreements
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Debt Disclosure [Text Block]
9.
Debt and Other Financing Arrangements
 
On
March 20, 2014,
the Company entered into an equipment financing arrangement (“Loan Agreement”) with Banc of America Leasing & Capital, LLC, which it amended on
August 8, 2014,
September 15, 2015
and
October 30, 2017.
The terms of this arrangement are detailed in the
10
-K.
 
The weighted average interest rate for all notes related to the Loan Agreement for the quarter ended
March 31, 2018
was
3.4%,
and represented
$28
thousand of interest expense as compared to a rate of
2.8%
and interest expense of
$22
thousand for the comparable period in
2017.
As of
March 31, 2018,
the interest rate was
3.5%
and there was
$3.1
million of outstanding debt related to the loan. The Company was in compliance with all loan covenants as of
March 31, 2018.
 
The annual principal repayment requirements for debt obligations as of
March 31, 2018
were as follows (in
000’s
):
 
  2018   $ 718  
  2019    
891
  
  2020    
702
  
  2021    
446
  
  2022    
381
  
  Total long-term debt    
3,138
  
  Less current portion of long-term debt    
(957
 )
  Total long-term debt, net of current portion   $
2,181
  
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 10 - Significant Customers
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Concentration Risk Disclosure [Text Block]
10.
Significant Customers
 
The Company had
one
customer that represented
32%
of revenue for the
three
months ended
March 31, 2018
and
36%
for the total revenue for the
three
months ended
March 31, 2017.
The Company had
two
customers that exceeded
10%
of the total accounts receivable balance as of
March 31, 2018
and
one
customer that exceeded
10%
of the total accounts receivable balance as of
December 31, 2017.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 11 - Recently Adopted Accounting Pronouncements
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]
11.
Recently Adopted Accounting Pronouncements
 
In
May 
2014,
the Financial Accounting Standard’s Board (“FASB”) issued Accounting Standards Update (“ASU”)
No.
 
2014
-
09,
“Revenue from Contracts with Customers”. The guidance in this update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (for example, insurance contracts or lease contracts). The guidance in this update supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic
605,
“Revenue Recognition”, and most industry-specific guidance throughout the Industry Topics of the Codification.
 
Effective
January 
1,
2018,
the Company adopted the requirements of Topic
606,
“Revenue from Contracts with Customers,” using the modified retrospective method, which requires the recognition of the cumulative effect of initially applying the standard (if any) as an adjustment to opening retained earnings for the fiscal year beginning
January 
1,
2018.
  The adoption of Topic
606
did
not
result in the recognition of a cumulative adjustment to opening retained earnings under the modified retrospective approach, nor did it have a material effect on the Company’s financial position or results of operations.  The adoption of this topic requires additional disclosures within the notes to the financial statements, as disclosed in Note
13
– “Revenue”.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 12 - Accounting Pronouncements Issued But Not Yet Effective
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
12.
Accounting Pronouncements Issued But
Not
Yet Effective
 
In
February 2016,
the FASB issued ASU
2016
-
02,
“Leases”, which introduces the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. The new standard establishes a right-of-use ("ROU") model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than
12
months. The new standard will become effective for fiscal years beginning after
December 15, 2018
and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.
 
In
February 2018,
the FASB issued ASU
2018
-
02,
“Income Statement – Reporting Comprehensive Income” (Topic
220
) Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which will allow a reclassification from accumulated other comprehensive income to retained earnings for the tax effects resulting from the Tax Cuts and Jobs Act (Tax Reform Act) that are stranded in accumulated other comprehensive income. This standard also requires certain disclosures about stranded tax effects. ASU
2018
-
2,
however, does
not
change the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations. ASU
2018
-
02
will be effective for the Company’s fiscal year
2020,
with the option to early adopt at any time prior to the effective date. It must be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Reform Act is recognized. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.
 
In
March 2018,
the FASB issued ASU
2018
-
05,
 “Income Taxes (Topic
740
): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No.
118”,
which updates the income tax accounting in U.S. GAAP to reflect the Securities and Exchange Commission (“SEC”) interpretive guidance released on
December 22, 2017,
when the Tax Act was signed into law. The Company is currently evaluating the impacts the adoption of this accounting guidance will have on its consolidated financial statements.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 13 - Revenue
 3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]
13.
Revenue
 
Adoption of ASC Topic
606,
“Revenue from Contracts with Customers”
 
On
January 
1,
2018,
the Company adopted Topic
606
using the modified retrospective method.  The adoption of Topic
606
did
not
have a material effect on the Company’s financial position or results of operations.
 
Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (
none
of which is variable) we expect to be entitled to in exchange for those services. We typically invoice customers monthly for services provided and payments are generally due within
30
to
60
days of the invoice date.
 
The table below disaggregates our external revenue by major source.  For additional revenue detail relating to geographic breakdown of sales, see Note
5
– “Business Segment Reporting”.
 
      Three Months Ended
   
 		  
 		 March 31,
2018		  
 		 March 31,
2017
      (in 000's)
  Testing   $
9,997
     $
9,385
  
  Shipping/Collection (hair)    
824
      
684
  
  Other    
114
      
140
  
  Total Revenue   $
10,935
     $
10,209
  
 
Testing Revenue
 
Testing revenue is our primary service. This primarily represents drug and alcohol tests for drugs of abuse using hair, performed in our forensic laboratory in California. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer.  Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue.
 
Revenue is measured as the amount of consideration we expect to receive in exchange for providing services.  Sales and other taxes we pay concurrent with revenue-producing activities are excluded from revenue. Incidental items, such as storage of samples and data, that are immaterial in the context of the contract are recognized as expense.   
 
Shipping and Hair Collection Revenue
 
Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (“sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by
third
parties who have contracted with the Company. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer.  
 
Revenue is measured as the amount of consideration we expect to receive in exchange for providing services.  As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues.
 
Other Revenue
 
Other revenue represents several items including; urine testing performed by other labs, medical review officer charges, legal/testifying services, a retail test which is sent to the laboratory for testing, and other miscellaneous charges. The total of all of these items is approximately
1%
of sales. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time.  
 
Practical Expedients and Exemptions
 
We generally expense sales commissions when incurred because the amortization period is
one
year or less. These costs are recorded within selling, general and administrative expense.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Stock-based Compensation (Tables)
 3 Months Ended
Mar. 31, 2018
Notes Tables  
Share-based Compensation, Stock Options, Activity [Table Text Block]
   
 
 		  
 
 		  
Number of
Shares		  
 
 		 Weighted Average
Exercise Price
Per Share		  
 
 		 Weighted Average
Remaining
Contractual Life		  
 
 		 Aggregate
Intrinsic
Value
(1)
  Outstanding, December 31, 2017    
279
     $
15.40
      
8.7 years
     $
1,436
  
  Granted    
-
      
 
      
 
      
 
  
  Exercised    
-
      
 
      
 
      
 
  
  Forfeited    
-
      
 
      
 
      
 
  
  Outstanding, March 31, 2018    
279
     $
15.40
      
8.4 years
     $
1,659
  
                                   
  Exercisable, March 31, 2018    
56
     $
12.61
      
7.9 years
     $
491
  
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
      Number of Shares   Weighted Average Price per Share
(2)
   Weighted Average Fair Value
(2)
               
  Outstanding & Unvested, December 31, 2017    
32
     $
16.08
     $
516
  
  Granted    
-
      
 
      
 
  
  Converted to common stock    
-
      
 
      
 
  
  Cancelled    
-
      
 
      
 
  
  Forfeited    
-
      
 
      
 
  
  Outstanding & Unvested, March 31, 2018    
32
     $
16.08
     $
516
  
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 4 - Basic and Diluted Net Income Per Share (Tables)
 3 Months Ended
Mar. 31, 2018
Notes Tables  
Schedule of Weighted Average Number of Shares [Table Text Block]
      Three Months Ended
      March 31,
2018		   March 31,
2017
  Weighted average common shares outstanding, basic    
5,492
      
5,460
  
  Dilutive common equivalent shares    
64
      
73
  
  Weighted average common shares outstanding, diluted    
5,556
      
5,533
  
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 5 - Business Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2018
Notes Tables  
Revenue from External Customers by Geographic Areas [Table Text Block]
      Three Months Ended
      March 31,
2018		   March 31,
2017
  Consolidated Revenue:        
  United States   $
7,323
     $
6,468
  
  Brazil    
3,526
      
3,696
  
  Other    
86
      
45
  
  Total Revenue   $
10,935
     $
10,209
  
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 9 - Debt and Other Financing Agreements (Tables)
 3 Months Ended
Mar. 31, 2018
Notes Tables  
Schedule of Long-term Debt Instruments [Table Text Block]
  2018   $ 718  
  2019    
891
  
  2020    
702
  
  2021    
446
  
  2022    
381
  
  Total long-term debt    
3,138
  
  Less current portion of long-term debt    
(957
 )
  Total long-term debt, net of current portion   $
2,181
  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 13 - Revenue (Tables)
 3 Months Ended
Mar. 31, 2018
Notes Tables  
Disaggregation of Revenue [Table Text Block]
      Three Months Ended
   
 		  
 		 March 31,
2018		  
 		 March 31,
2017
      (in 000's)
  Testing   $
9,997
     $
9,385
  
  Shipping/Collection (hair)    
824
      
684
  
  Other    
114
      
140
  
  Total Revenue   $
10,935
     $
10,209
  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Stock-based Compensation (Details Textual)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2018
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 199
Share Price | $ / shares $ 21.36
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $ $ 0.8
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 2 years 255 days
Stock Incentive Plan 2006 [Member]  
Common Stock, Capital Shares Reserved for Future Issuance 510
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Stock-based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Outstanding (in shares) 279  
Outstanding, weighted average exercise price (in dollars per share) $ 15.40  
Outstanding, Weighted average remaining contractual life (Year) 8 years 146 days 8 years 255 days
Outstanding, aggregate intrinsic value [1] $ 1,659 $ 1,436
Granted (in shares)  
Granted, weighted average exercise price (in dollars per share)  
Exercised (in shares)  
Exercised, weighted average exercise price (in dollars per share)  
Forfeited (in shares)  
Forfeited, weighted average exercise price (in dollars per share)  
Outstanding (in shares) 279 279
Outstanding, weighted average exercise price (in dollars per share) $ 15.40 $ 15.40
Exercisable (in shares) 56  
Exercisable, weighted average exercise price (in dollars per share) $ 12.61  
Exercisable, Weighted average remaining contractual life (Year) 7 years 328 days  
Exercisable, aggregate intrinsic value [1] $ 491  
[1] The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company's stock on March 31, 2018 ($21.36) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Share-based Compensation - Nonvested Award Activity (Details) - Stock Unit Award [Member] - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Outstanding & Unvested (in shares) 32  
Outstanding & Unvested, weighted average price per share (in dollars per share) [1] $ 16.08  
Outstanding & Unvested, weighted average fair value [1] $ 516 $ 516
Granted (in shares)  
Granted, weighted average price per share (in dollars per share) [1]  
Granted, weighted average fair value [1]  
Converted to common stock (in shares)  
Cancelled (in shares)  
Forfeited (in shares)  
Outstanding & Unvested (in shares) 32  
Outstanding & Unvested, weighted average price per share (in dollars per share) [1] $ 16.08  
[1] Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each grant of stock unit awards. The weighted average fair value is the weighted average share price times the number of shares.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 4 - Basic and Diluted Net Income Per Share - Basic and Diluted Shares Outstanding (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Weighted average common shares outstanding, basic (in shares) 5,492 5,460
Dilutive common equivalent shares (in shares) 64 73
Weighted average common shares outstanding, diluted (in shares) 5,556 5,533
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 5 - Business Segment Reporting (Details Textual)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Number of Operating Segments 1  
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]    
Number of Major Customers 1 1
Concentration Risk, Percentage 32.00% 36.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | BRAZIL    
Number of Major Customers 1  
Concentration Risk, Percentage 10.00%  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 5 - Business Segment Reporting - Summary of Revenues by Geographic Region (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenues $ 10,935 $ 10,209
UNITED STATES    
Revenues 7,323 6,468
BRAZIL    
Revenues 3,526 3,696
Other Foreign Countries [Member]    
Revenues $ 86 $ 45
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Subsequent Events (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Apr. 24, 2018
Mar. 31, 2018
Mar. 31, 2017
Common Stock, Dividends, Per Share, Declared   $ 0.18 $ 0.15
Subsequent Event [Member]      
Common Stock, Dividends, Per Share, Declared $ 0.18    
Dividends Payable $ 989    
Dividends Payable, Date to be Paid May 18, 2018    
Dividends Payable, Date of Record May 08, 2018    
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 9 - Debt and Other Financing Agreements (Details Textual) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Debt, Weighted Average Interest Rate 3.40% 2.80%
Interest Expense, Total $ 28 $ 22
Debt Instrument, Interest Rate, Effective Percentage 3.50%  
Long-term Debt, Total $ 3,138  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
2018 $ 718  
2019 891  
2020 702  
2021 446  
2022 381  
Total long-term debt 3,138  
Less current portion of long-term debt (957) $ (957)
Total long-term debt, net of current portion $ 2,181 $ 2,420
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 10 - Significant Customers (Details Textual) - Customer Concentration Risk [Member]
 3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Sales Revenue, Net [Member]      
Number of Major Customers 1 1  
Concentration Risk, Percentage 32.00% 36.00%  
Accounts Receivable [Member]      
Number of Major Customers 2   1
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 13 - Revenue (Details Textual)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Sales Revenue, Net [Member] | Product Concentration Risk [Member] | Other Revenue [Member]    
Concentration Risk, Percentage 1.00% 1.00%
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 13 - Revenue - Revenue by Major Source (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenues $ 10,935 $ 10,209
Testing [Member]    
Revenues 9,997 9,385
Shipping/Collection (Hair) [Member]    
Revenues 824 684
Other Revenue [Member]    
Revenues $ 114 $ 140
EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 33 150 1 true 13 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://http/20180331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://http/20180331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://http/20180331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) Sheet http://http/20180331/role/statement-condensed-consolidated-statements-of-income-and-comprehensive-income-unaudited Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://http/20180331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Note 1 - Basis of Presentation Sheet http://http/20180331/role/statement-note-1-basis-of-presentation Note 1 - Basis of Presentation Notes 6 false false R7.htm 006 - Disclosure - Note 2 - Cash and Cash Equivalents Sheet http://http/20180331/role/statement-note-2-cash-and-cash-equivalents Note 2 - Cash and Cash Equivalents Notes 7 false false R8.htm 007 - Disclosure - Note 3 - Stock-based Compensation Sheet http://http/20180331/role/statement-note-3-stockbased-compensation Note 3 - Stock-based Compensation Notes 8 false false R9.htm 008 - Disclosure - Note 4 - Basic and Diluted Net Income Per Share Sheet http://http/20180331/role/statement-note-4-basic-and-diluted-net-income-per-share Note 4 - Basic and Diluted Net Income Per Share Notes 9 false false R10.htm 009 - Disclosure - Note 5 - Business Segment Reporting Sheet http://http/20180331/role/statement-note-5-business-segment-reporting Note 5 - Business Segment Reporting Notes 10 false false R11.htm 010 - Disclosure - Note 6 - Fair Value Measurements Sheet http://http/20180331/role/statement-note-6-fair-value-measurements Note 6 - Fair Value Measurements Notes 11 false false R12.htm 011 - Disclosure - Note 7 - Subsequent Events Sheet http://http/20180331/role/statement-note-7-subsequent-events Note 7 - Subsequent Events Notes 12 false false R13.htm 012 - Disclosure - Note 8 - Commitments and Contingencies Sheet http://http/20180331/role/statement-note-8-commitments-and-contingencies Note 8 - Commitments and Contingencies Notes 13 false false R14.htm 013 - Disclosure - Note 9 - Debt and Other Financing Agreements Sheet http://http/20180331/role/statement-note-9-debt-and-other-financing-agreements Note 9 - Debt and Other Financing Agreements Notes 14 false false R15.htm 014 - Disclosure - Note 10 - Significant Customers Sheet http://http/20180331/role/statement-note-10-significant-customers Note 10 - Significant Customers Notes 15 false false R16.htm 015 - Disclosure - Note 11 - Recently Adopted Accounting Pronouncements Sheet http://http/20180331/role/statement-note-11-recently-adopted-accounting-pronouncements Note 11 - Recently Adopted Accounting Pronouncements Notes 16 false false R17.htm 016 - Document - Note 12 - Accounting Pronouncements Issued But Not Yet Effective Sheet http://http/20180331/role/statement-note-12-accounting-pronouncements-issued-but-not-yet-effective Note 12 - Accounting Pronouncements Issued But Not Yet Effective Uncategorized 17 false false R18.htm 017 - Disclosure - Note 13 - Revenue Sheet http://http/20180331/role/statement-note-13-revenue Note 13 - Revenue Uncategorized 18 false false R19.htm 018 - Disclosure - Note 3 - Stock-based Compensation (Tables) Sheet http://http/20180331/role/statement-note-3-stockbased-compensation-tables Note 3 - Stock-based Compensation (Tables) Uncategorized 19 false false R20.htm 019 - Disclosure - Note 4 - Basic and Diluted Net Income Per Share (Tables) Sheet http://http/20180331/role/statement-note-4-basic-and-diluted-net-income-per-share-tables Note 4 - Basic and Diluted Net Income Per Share (Tables) Uncategorized 20 false false R21.htm 020 - Disclosure - Note 5 - Business Segment Reporting (Tables) Sheet http://http/20180331/role/statement-note-5-business-segment-reporting-tables Note 5 - Business Segment Reporting (Tables) Uncategorized 21 false false R22.htm 021 - Disclosure - Note 9 - Debt and Other Financing Agreements (Tables) Sheet http://http/20180331/role/statement-note-9-debt-and-other-financing-agreements-tables Note 9 - Debt and Other Financing Agreements (Tables) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 13 - Revenue (Tables) Sheet http://http/20180331/role/statement-note-13-revenue-tables Note 13 - Revenue (Tables) Uncategorized 23 false false R24.htm 023 - Disclosure - Note 3 - Stock-based Compensation (Details Textual) Sheet http://http/20180331/role/statement-note-3-stockbased-compensation-details-textual Note 3 - Stock-based Compensation (Details Textual) Uncategorized 24 false false R25.htm 024 - Disclosure - Note 3 - Stock-based Compensation - Stock Option Activity (Details) Sheet http://http/20180331/role/statement-note-3-stockbased-compensation-stock-option-activity-details Note 3 - Stock-based Compensation - Stock Option Activity (Details) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 3 - Share-based Compensation - Nonvested Award Activity (Details) Sheet http://http/20180331/role/statement-note-3-sharebased-compensation-nonvested-award-activity-details Note 3 - Share-based Compensation - Nonvested Award Activity (Details) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 4 - Basic and Diluted Net Income Per Share - Basic and Diluted Shares Outstanding (Details) Sheet http://http/20180331/role/statement-note-4-basic-and-diluted-net-income-per-share-basic-and-diluted-shares-outstanding-details Note 4 - Basic and Diluted Net Income Per Share - Basic and Diluted Shares Outstanding (Details) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 5 - Business Segment Reporting (Details Textual) Sheet http://http/20180331/role/statement-note-5-business-segment-reporting-details-textual Note 5 - Business Segment Reporting (Details Textual) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 5 - Business Segment Reporting - Summary of Revenues by Geographic Region (Details) Sheet http://http/20180331/role/statement-note-5-business-segment-reporting-summary-of-revenues-by-geographic-region-details Note 5 - Business Segment Reporting - Summary of Revenues by Geographic Region (Details) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 7 - Subsequent Events (Details Textual) Sheet http://http/20180331/role/statement-note-7-subsequent-events-details-textual Note 7 - Subsequent Events (Details Textual) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 9 - Debt and Other Financing Agreements (Details Textual) Sheet http://http/20180331/role/statement-note-9-debt-and-other-financing-agreements-details-textual Note 9 - Debt and Other Financing Agreements (Details Textual) Uncategorized 31 false false R32.htm 031 - Disclosure - Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) Sheet http://http/20180331/role/statement-note-9-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) Uncategorized 32 false false R33.htm 032 - Disclosure - Note 10 - Significant Customers (Details Textual) Sheet http://http/20180331/role/statement-note-10-significant-customers-details-textual Note 10 - Significant Customers (Details Textual) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 13 - Revenue (Details Textual) Sheet http://http/20180331/role/statement-note-13-revenue-details-textual Note 13 - Revenue (Details Textual) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 13 - Revenue - Revenue by Major Source (Details) Sheet http://http/20180331/role/statement-note-13-revenue-revenue-by-major-source-details Note 13 - Revenue - Revenue by Major Source (Details) Uncategorized 35 false false All Reports Book All Reports pmd-20180331.xml pmd-20180331.xsd pmd-20180331_cal.xml pmd-20180331_def.xml pmd-20180331_lab.xml pmd-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 53 0001171843-18-003112-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-18-003112-xbrl.zip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end